Skip to content

Clinical trials

Completed Child Development Disorders, Pervasive trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Child Development Disorders, Pervasive Status: Completed Country / region: United States Clear all

53 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20021
20033
20044
20051
20063
20075
20082
20094
20108
20112
20122
20134
20153
20172
20181
20201
20211
20231
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed53

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Massachusetts General Hospital7
Yale University6
Indiana University4
Children's Hospital Medical Center, Cincinnati3
National Institute of Mental Health (NIMH)3
Drexel University College of Medicine2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2
Ohio State University2
University of Pittsburgh2
Boston Children's Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Child Development Disorders, Pervasive53
Autistic Disorder40
Autism Spectrum Disorder26
Asperger Syndrome23
Attention Deficit Disorder with Hyperactivity8
Anxiety Disorders3
Bipolar Disorder3
Oppositional Defiant Disorder3
Conduct Disorder2
Neurodevelopmental Disorders2

Trials

Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.